Clinical Report: Persistent Leukopenia Associated with Long-term Use of Voglibose

Overview

Revise to include a clearer timeline of leukopenia development and treatment response.

Background

Alpha-glucosidase inhibitors, including voglibose, are commonly used in managing type 2 diabetes due to their favorable safety profile. However, hematological adverse effects, such as leukopenia, are rarely reported. Understanding these potential side effects is crucial for ensuring patient safety and effective diabetes management.

Data Highlights

Key Findings

• Persistent leukopenia was observed in a 71-year-old male with type 2 diabetes over five years.
• Bone marrow biopsy indicated hypoplasia, and conventional leukopoietic treatments were ineffective.
• A multidisciplinary review identified long-term voglibose use as a probable cause of leukopenia.
• Switching from voglibose to acarbose resulted in a significant increase in WBC count.
• The Naranjo score of 7 supported the association between voglibose and leukopenia.

Clinical Implications

Highlight the importance of regular blood count monitoring for patients on voglibose.

Conclusion

Reinforce the rarity of this adverse effect and the need for clinician awareness.

Related Resources & Content

1. Frontiers in Endocrinology, 2026 -- Inavolisib-induced fulminant-like diabetes and hyperosmolar hyperglycemic state: a case report
2. The Journal of Clinical Endocrinology & Metabolism, 2021 -- Management of Patients with Diabetes Resulting from Exocrine Pancreatic Disorders
3. Drugs - Real World Outcomes, 2019 -- Efficacy of V-Go® in Real-World Management of Type 2 Diabetes: Findings from a Prospective Observational Study
4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
5. Acarbose - LiverTox® - NCBI Bookshelf
6. The ASCO Post — Can Diabetes Affect the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Cancer?
7. Drug-induced agranulocytosis: a disproportionality analysis and umbrella review
8. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
9. Acarbose - LiverTox® - NCBI Bookshelf